DNA aptamers used to inhibit reverse transcriptase

By designing DNA aptamers with specific sequences to bind to reverse transcriptase and regulating its activity, the interference problem of reverse transcriptase in molecular biology experiments has been solved, and the controllable inhibition and recovery of reverse transcriptase function has been achieved, which is suitable for PCR assays.

CN123125331APending Publication Date: 2026-11-17INTEGRATED DNA TECHNOLOGIES INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202580025529.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-03-29
Filing Date
2025-03-28
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

In the prior art, the function of reverse transcriptase is harmful in some cases, and its activity needs to be effectively controlled to avoid interfering with molecular biology experiments.

Method used

A DNA aptamer with a specific nucleotide sequence was developed that can specifically bind to reverse transcriptase, and its activity can be controlled by regulating temperature to inhibit the function of reverse transcriptase.

Benefits of technology

A method for reversibly inhibiting reverse transcriptase is provided, which can inhibit reverse transcriptase activity at room temperature, avoid PCR interference, and restore its function when needed. It is suitable for large-scale PCR assays, improving experimental efficiency and cost-effectiveness.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123125331A_ABST
    Figure CN123125331A_ABST
Patent Text Reader

Abstract

DNA aptamers are disclosed. Related compositions and kits are also provided. Methods for amplifying target DNA sequences using said DNA aptamers and methods for identifying said DNA aptamers are also disclosed.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Cross-references to related applications

[0002] This patent application claims the benefit of U.S. Provisional Patent Application No. 63 / 571,790, filed on March 29, 2024, which is hereby incorporated in its entirety by reference.

[0003] By incorporating materials submitted electronically.

[0004] By reference, the computer-readable nucleotide / amino acid sequence listing submitted at the same time and identified as follows is incorporated in its entirety: a 139,096-byte Extensible Markup Language (XML) file named "772843.xml", created on March 28, 2025. Background Technology

[0005] Aptamers are small RNA or DNA molecules capable of forming secondary and tertiary structures that can specifically bind to proteins or other cellular targets.

[0006] Reverse transcriptases (RT enzymes) are enzymes that participate in viral genome replication using RNA-dependent DNA polymerases and the RNase H activity of RT enzymes. RT enzymes derived from retroviruses were first discovered in 1970 by David Baltimore and Howard Temin, and have since revolutionized molecular biology through many applications, including RT-PCR and sequencing of isolated RNA. The three most commonly used RT enzymes for cDNA synthesis are derived from retroviruses: Moloney murineleukemia virus (MMLV), avian myeloblastosis virus (AMV), and human immunodeficiency virus type 1 (HIV-1) (Coffin et al., Annu. Rev. Virol., 3(1): 29-51 (2016)).

[0007] In some cases, unwanted reverse transcriptase function is harmful. Therefore, there is an unmet need for control over reverse transcriptase function. Summary of the Invention

[0008] One aspect of the present invention provides a DNA aptamer comprising a nucleotide sequence having at least 95% sequence identity with at least one of SEQ ID NO: 2-101.

[0009] Another aspect of the invention provides compositions and kits related to the DNA aptamers of the invention.

[0010] Another aspect of the present invention provides a method for amplifying a target DNA sequence, the method comprising: (a) providing a composition according to one aspect of the present invention, the composition further comprising at least one oligonucleotide primer and at least one sample comprising at least one target DNA sequence, wherein the composition is at a temperature of about 20°C to about 30°C, and wherein the reverse transcriptase is bound to the at least one DNA aptamer; (b) raising the temperature of the composition to release the reverse transcriptase from the at least one DNA aptamer; (c) hybridizing the at least one oligonucleotide primer to the at least one sample comprising at least one target DNA sequence; and (d) initiating DNA polymerase activity and extending the primer with the DNA polymerase to provide an additional target DNA sequence.

[0011] Another aspect of the invention provides a method for identifying at least one DNA aptamer that inhibits at least one reverse transcriptase, the method comprising: (a) providing a DNA aptamer library containing the DNA aptamer; (b) in the presence of an RNA aptamer, bringing the DNA aptamer into contact with the at least one reverse transcriptase; (c) separating a DNA aptamer having a high affinity for the at least one reverse transcriptase from a DNA aptamer having a low affinity for the at least one reverse transcriptase; and (d) amplifying the DNA aptamer having a high affinity for the at least one reverse transcriptase to obtain an enriched DNA aptamer library, wherein the at least one DNA aptamer that inhibits the at least one reverse transcriptase can be identified from the enriched DNA aptamer library. Attached Figure Description

[0012] Figure 1A and Figure 1B This is a set of figures showing the results of sequencing an enriched DNA aptamer library, which was obtained using a modified ligand index enrichment system evolution (SELEX) protocol with added ( Figure 1B ) and not adding ( Figure 1A It was created using RNA aptamers. Detailed Implementation

[0013] One aspect of the present invention provides a DNA aptamer comprising a nucleotide sequence having at least about 95% sequence identity (i.e., at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% sequence identity) with at least one of SEQ ID NOs: 2-101. Another aspect provides a DNA aptamer comprising a nucleotide sequence having at least about 95% sequence identity (i.e., at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% sequence identity) with at least one SEQ ID NO of the DNA aptamer in Table 1.

[0014] Table 1

[0015]

[0016]

[0017]

[0018]

[0019]

[0020]

[0021]

[0022]

[0023]

[0024]

[0025]

[0026] In Table 1, and throughout this application, FAM refers to dye; ZEN refers to N,N-diethyl-4-(4-nitronaphth-1-ylazo)-aniline; 3IABkFQ refers to Iowa Black. TM FQ quencher has a broad absorption spectrum in the range of 420 nm to 620 nm, with a peak absorption at 531 nm; YakYel refers to Yakma Yellow. TM Dye (a trademark of ELITech Group); TexRd-XN refers to 5' Texas Red. TM -X (NHS ester) (trademark of Molecular Probes / Life Technologies); TAO refers to the quencher; 3IAbRQSp refers to the quencher; CY5 refers to the red dye; 3Phos refers to 3' phosphorylation; 3SpC3 refers to the 3' C3 spacer; 3ddC refers to 3' dideoxy-C; 3InvdT refers to 3' reverse dT; and 3AmMO refers to the 3' amino modification. In Table 1, rC refers to the RNA cytosine base, rU refers to the RNA uracil base, rA refers to the RNA adenine base, and rG refers to the RNA guanine base.

[0027] DNA aptamers can have any suitable length, i.e., can contain any number of amino acids, provided that the DNA aptamer retains its biological activity, such as its ability to specifically bind to reverse transcriptase. In one aspect of the invention, the DNA aptamer comprises about 50 to about 90 nucleotides (i.e., about 55 to about 89 nucleotides, about 60 to about 88 nucleotides, about 65 to about 87 nucleotides, about 70 to about 86 nucleotides, about 72 to about 85 nucleotides, about 74 to about 85 nucleotides, about 76 to about 85 nucleotides, about 78 to about 84 nucleotides, about 79 to about 84 nucleotides, about 81 to about 83 nucleotides, or about 82 nucleotides). In this respect, DNA aptamers contain approximately 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 81, 82, 83, 84, 85, or 90 nucleotides.

[0028] DNA aptamers may contain adaptor sequences. In this respect, adaptor sequences can be of any suitable length. For example, adaptor sequences can be about 5 to about 30 nucleotides, about 10 to about 25 nucleotides, about 15 to about 25 nucleotides, about 20 to about 22 nucleotides, or about 21 nucleotides. DNA aptamers may contain about two adaptor sequences.

[0029] In one aspect of the invention, the DNA aptamer comprises a nucleotide sequence having at least about 95% (i.e., at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100%) sequence identity with at least one of the following: SEQ ID NO: 29 (M21_28), 45 (M21_44), 60 (M21+RNA_9), 72 (M21+RNA_21), 76 (M21+RNA_25), 78 (M 21+RNA_27), 79(M21+RNA_28), 81(M21+RNA_30), 82(M21+RNA_31), 83(M21+RNA_32) , 90 (M21+RNA_39), 91 (M21+RNA_40), 93 (M21+RNA_42), 94 (M21+RNA_43), 95 (M21+RN A_44), 121 (M21+RNA_9_3Phos), 134 (M21+RNA_11_3Phos), and 135 (M21+RNA_47_3Phos). In one aspect of the invention, the DNA aptamer comprises a nucleotide sequence having at least about 95% (at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100%) sequence identity with at least one of SEQ ID NO: 121 (M21+RNA_9_3Phos), 134 (M21+RNA_11_3Phos), and 135 (M21+RNA_47_3Phos).

[0030] According to one aspect of the invention, the DNA aptamer comprises at least one (e.g., one or two) 1-20 bp (1-19 bp, 1-18 bp, 1-17 bp, 1-16 bp, 1-15 bp, 1-14 bp, 1-13 bp, 1-12 bp, 1-11 bp, 1-10 bp, 1-9 bp, 1-8 bp, 1-7 bp, 1-6 bp, 1-5 bp, 1-4 bp, 1-3 bp, 1-2 bp, or 1 bp) truncation. The DNA aptamer can be truncated for any suitable reason, including reducing the size of the DNA aptamer to alter its affinity for reverse transcriptase (e.g., increasing affinity). In one aspect, the DNA aptamer comprises a truncated aptamer of approximately 20 bp.

[0031] DNA aptamers can be modified to improve their stability. DNA aptamers can be, for example, glycosylated, amidated, carboxylated, phosphorylated, esterified, N-acylated, cyclized via, for example, disulfide bonds, or converted to an acid addition salt and / or optionally dimerized or polymerized, or conjugated. For example, the 3' or 5' end can be phosphorylated, or a C3 spacer, dideoxy-C, or reverse dT can be added, or amino modifiers can be used. Modifications can also prevent or reduce nonspecific binding and amplification. In one aspect of the invention, the DNA aptamer comprises a nucleotide sequence having at least 95% (i.e., at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100%) sequence identity with at least one of SEQ ID NO: NO: 121-125. In another aspect of the invention, the DNA aptamer comprises 3'-phosphorylation.

[0032] In one aspect of the invention, the DNA aptamer has a binding affinity (K0) for reverse transcriptase. d Binding affinity can be calculated using any suitable method. In some aspects of the invention, the DNA aptamer has high specificity for reverse transcriptase, and / or high binding affinity for reverse transcriptase, and does not bind specifically to proteins that are not reverse transcriptases (e.g., the DNA aptamer binds to reverse transcriptase with an affinity at least 10, 100, 1,000, 10,000, or 100,000 times higher than that of non-reverse transcriptases).

[0033] In another aspect of the invention, the DNA aptamer specifically binds to reverse transcriptase and has a high binding affinity for it. In another aspect of the invention, the DNA aptamer binds to reverse transcriptase at about 20°C to about 30°C (e.g., about 21°C to about 29°C, about 22°C to about 28°C, about 23°C to about 27°C, about 24°C to about 26°C, or about 25°C), thereby inhibiting reverse transcriptase. In another aspect of the invention, the DNA aptamer cannot inhibit reverse transcriptase at about 45°C to about 55°C (e.g., about 46°C to about 54°C, about 47°C to about 53°C, about 48°C to about 52°C, about 49°C to about 51°C, or about 50°C).

[0034] One aspect of this invention provides users with the ability to tightly control reverse transcriptase by controlling the binding affinity of the DNA aptamer and thus inhibiting its function. The DNA aptamer can not only be “turned on” and “turned off” by the user through temperature adjustment, but it is also stable enough to allow for sequential switching between on and off. In this respect, the DNA aptamer of this invention features reversible binding and inhibition. These features of the DNA aptamer of this invention open up new possibilities for novel laboratory assays with enhanced functionality. For example, compositions containing the DNA aptamer of this invention can be used in the “master mixture” of large-scale PCR assays and can be used with automation because the master mixture inhibits reverse transcriptase activity at room temperature for an extended period (e.g., at least 4 hours).

[0035] The DNA aptamer of one aspect of the present invention can be used in any application where undesirable reverse transcriptase function causes problems. Reverse transcriptase has multiple functions, including RNA-dependent DNA polymerase activity, terminal transferase activity, and the ability to promote template conversion in cDNA synthesis. It is known that reverse transcriptase interferes with probe-based qPCR upon template addition, and this is believed to occur through qPCR reagent consumption and the generation of uncharacterized PCR-interfering nucleic acid products. Therefore, the DNA aptamer of one aspect of the present invention solves this problem by binding to and inhibiting reverse transcriptase, and thus preventing reverse transcriptase from functioning before it is needed.

[0036] It was also found that the DNA aptamers of the present invention reversibly inhibit reverse transcriptase at relatively low DNA aptamer to reverse transcriptase ratios and concentrations. This also provides a highly efficient and cost-effective product.

[0037] Any suitable reverse transcriptase can be used. In one aspect of the invention, the reverse transcriptase is derived from Moloney murine leukemia virus (MMLV), avian myeloblastoma virus (AMV), or human immunodeficiency virus type 1 (HIV-1). In another aspect of the invention, the reverse transcriptase is derived from MMLV. In yet another aspect of the invention, the reverse transcriptase comprises a nucleotide sequence having at least 95% (i.e., at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100%) sequence identity with SEQ ID NO: 132 (M21).

[0038] The M21 protein described herein may include its functional variants. Functional variants may, for example, comprise the sequence of the parent protein having at least one conserved amino acid substitution. Conserved amino acid substitutions are known in the art and include substitutions in which one amino acid having certain physical and / or chemical properties is exchanged for another amino acid having the same chemical or physical properties. For example, a conserved amino acid substitution may be one acidic amino acid replacing another acidic amino acid (e.g., Asp or Glu), one amino acid with a nonpolar side chain replacing another amino acid with a nonpolar side chain (e.g., Ala, Gly, Val, Ile, Leu, Met, Phe, Pro, Trp, Val, etc.), one basic amino acid replacing another basic amino acid (Lys, Arg, etc.), one amino acid with a polar side chain replacing another amino acid with a polar side chain (Asn, Cys, Gln, Ser, Thr, Tyr, etc.), etc.

[0039] Alternatively or additionally, the functional variant may comprise the amino acid sequence of the parent protein having at least one non-conserved amino acid substitution. In this case, it is preferred that the non-conserved amino acid substitution does not interfere with or inhibit the biological activity of the functional variant. Preferably, the non-conserved amino acid substitution enhances the biological activity of the functional variant, such that the biological activity of the functional variant is increased compared to the parent protein.

[0040] The aptamers and reverse transcriptases described herein may comprise, consist substantially of, or be composed of the specified nucleic acid sequences described herein, such that other components of the sequence (e.g., other nucleic acids) do not substantially alter the biological activity of the aptamer and reverse transcriptase.

[0041] Aptamers can be prepared by any suitable method. For example, aptamers can be synthetic or recombinant.

[0042] Aptamers can be isolated and / or purified. DNA aptamer compositions can be purified using any suitable method. For example, purification by polyacrylamide gel electrophoresis (PAGE). As used herein, the term "isolated" means that it has been removed from its natural environment. As used herein, the term "purified" means that the purity has been improved, where "purity" is a relative term and is not necessarily interpreted as absolute purity. For example, the purity can be at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, or it can be about 100%.

[0043] This document also provides compositions comprising at least one DNA aptamer according to one aspect of the invention.

[0044] The compositions of the present invention may further include at least one reverse transcriptase. In one aspect of the invention, the reverse transcriptase is M21.

[0045] The composition may contain any suitable excipient. In one aspect of the invention, the composition further comprises deoxynucleoside triphosphates (dNTPs), buffer solutions, or combinations thereof. The excipient may be any excipient conventionally used for the DNA aptamers of the specific invention in question.

[0046] In one aspect of the invention, the DNA aptamer is present in the composition at a reverse transcriptase:aptamer ratio of about 1:2 to about 1:8 (i.e., about 1:2 to about 1:8, about 1:3 to about 1:8, about 1:4 to about 1:8, about 1:5 to about 1:8, about 1:5 to about 1:7, about 1:5.5 to about 1:6.5 or about 1:6).

[0047] The composition may contain any number of DNA aptamers. For example, the composition may contain three DNA aptamers: a first DNA aptamer (aptamer 1), a second DNA aptamer (aptamer 2), optionally a third DNA aptamer (aptamer 3), and optionally a fourth aptamer (aptamer 4), etc. In one aspect of the invention, the composition contains a reverse transcriptase:aptamer 1:aptamer 2 in a ratio of about 1:2:2 to about 1:8:8 (i.e., about 1:2:2 to about 1:8:8, about 1:3:3 to about 1:8:8, about 1:4:4 to about 1:8:8, about 1:5:5 to about 1:8:8, about 1:5:5 to about 1:7:7, about 1:5.5:5.5 to about 1:6.5:6.5, or about 1:6:6).

[0048] In one aspect of the invention, the first DNA aptamer comprises a nucleotide sequence having at least 95% (i.e., at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100%) sequence identity with SEQ ID NO: 121 (M21+RNA_9_3Phos), the second DNA aptamer comprises a nucleotide sequence having at least 95% (i.e., at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100%) sequence identity with SEQ ID NO: 134 (M21+RNA_11_3Phos), and the third DNA aptamer comprises a nucleotide sequence having at least 95% (i.e., at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100%) sequence identity with SEQ ID NO: 135 (M21+RNA_47_3Phos).

[0049] In another aspect of the invention, the first DNA aptamer comprises a nucleotide sequence having at least 95% (i.e., at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100%) sequence identity with SEQ ID NO: 121 (M21+RNA_9_3Phos), the second DNA aptamer comprises a nucleotide sequence having at least 95% (i.e., at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100%) sequence identity with SEQ ID NO: 134 (M21+RNA_11_3Phos), and the third DNA aptamer comprises a nucleotide sequence having at least 95% (i.e., at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100%) sequence identity with SEQ ID NO: 135 (M21+RNA_47_3Phos) has a nucleotide sequence with at least 95% (i.e., at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100%) sequence identity, and wherein said composition comprises reverse transcriptase:aptor 1:aptor 2:aptor 3 in a ratio of about 1:2:2:2 to about 1:8:8:8. In one aspect of the invention, said composition comprises reverse transcriptase:aptor 1:aptor 2:aptor 3 in a ratio of about 1:6:6:6.

[0050] In one aspect of the invention, the composition comprises an RNA aptamer. Any suitable RNA aptamer can be used. In another aspect of the invention, the RNA aptamer comprises a sequence having at least 95% (i.e., at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100%) sequence identity with SEQ ID NO: 1.

[0051] One aspect of the present invention provides a kit comprising the DNA aptamer of the present invention or the composition of the present invention. The kit may contain instructions, a container for containing the DNA aptamer or the composition, and any other components necessary or useful for carrying out the kit.

[0052] Another aspect of the invention is the use of the DNA aptamer in PCR. In this respect, one aspect of the invention provides a method for amplifying a target DNA sequence, the method comprising: (a) providing a composition according to one aspect of the invention, the composition further comprising at least one oligonucleotide primer, and at least one sample comprising at least one target DNA sequence, wherein the composition is at a temperature of about 20°C to about 30°C (e.g., about 21°C to about 29°C, about 22°C to about 28°C, about 23°C to about 27°C, about 24°C to about 26°C, or about 25°C), and wherein the reverse transcriptase is bound to the at least one DNA aptamer; (b) raising the temperature of the composition to release the reverse transcriptase from the at least one DNA aptamer; (c) hybridizing the at least one oligonucleotide primer to the at least one sample comprising at least one target DNA sequence; and (d) initiating DNA polymerase activity and extending the primer with the DNA polymerase to provide an additional target DNA sequence. In one aspect of the invention, in step (a), the composition is subjected to a temperature of about 20°C to about 30°C for at least about 4 hours (i.e., about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 12 hours, about 16 hours, about 20 hours, about 24 hours, or longer). In another aspect, in step (b), the temperature of the composition is raised to about 45°C to about 55°C (e.g., about 46°C to about 54°C, about 47°C to about 53°C, about 48°C to about 52°C, about 49°C to about 51°C, or about 50°C).

[0053] In this regard, another aspect of the invention provides a method for identifying at least one DNA aptamer that inhibits at least one reverse transcriptase, the method comprising: (a) providing a DNA aptamer library containing the DNA aptamer; (b) bringing the DNA aptamer close to the at least one reverse transcriptase in the presence of an RNA aptamer; (c) separating DNA aptamers with high affinity for the at least one reverse transcriptase from DNA aptamers with low affinity for the at least one reverse transcriptase; and (d) amplifying the DNA aptamer with high affinity for the at least one reverse transcriptase to obtain an enriched DNA aptamer library, wherein the at least one DNA aptamer that inhibits the at least one reverse transcriptase can be identified from the enriched DNA aptamer library. Unexpectedly, the identification of the DNA aptamer requires the presence of an RNA aptamer. Those skilled in the art can determine the meaning of "close to". Similarly, those skilled in the art can determine the cutoff values ​​for "high affinity" and "low affinity".

[0054] In another aspect of the invention, the RNA aptamer comprises a sequence having at least 95% (i.e., at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100%) sequence identity with SEQ ID NO: 1.

[0055] In another aspect of the invention, the reverse transcriptase comprises a nucleotide sequence having at least 95% (i.e., at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100%) sequence identity with SEQ ID NO: 132.

[0056] The methods disclosed herein may include the use of probes comprising dyes / fluorophores and quenchers for quantitative binding. Some of the oligonucleotides disclosed herein include fluorophores, which may include, but are not limited to, 6-carboxyfluorescein (FAM), 2'7'-dimethoxy-4'5'-dichloro-6-carboxyfluorescein (JOE), tetrachlorofluorescein (TET), 6-carboxyrhodamine (R6G), N,N,N;N'-tetramethyl-6-carboxyrhodamine (TAMRA), 6-carboxy-X-rhodamine (ROX); 1-dimethylaminonaphthyl-5-sulfonate, 1-phenylamino-8-naphthalenesulfonate, 2-p-tolylamino-6-naphthalenesulfonate, 5-(2'-aminoethyl)aminonaphthalene-1-sulfonic acid (EDANS), and coumarin dyes. Acridine dyes, indole-dicarbocyanine 3 (Cy3), indole-dicarbocyanine 5 (Cy5), indole-dicarbocyanine 5.5 (Cy5.5), 3-1-carboxypentyl)-3'-ethyl-5,5'-dimethyloxacarbocyanine (CyA); 1H,5H,11H,15H-xanthond[2,3,4-ij:5,6,7-i'j']diquinazine-18-onium, 9-[2(or 4)-[[[6-[2,5-dioxo-1-pyrrolidinyl)oxy]-6-oxohexyl]amino]sulfonyl]-4(or 2)-sulfophenyl]-2,3,6,7,12,13,16,17-octahydro-internal salt (TR or Texas Red) TM ), BODIPY™ dye, Yakima Yellow TM Dyes, benzoxazole, stilbene, and pyrene.

[0057] Some of the oligonucleotides disclosed herein include quenchers. Suitable quenchers may include dabcyl, Eclipse, etc. TM Quenching agents, BHQ1, BHQ2 and BHQ3, Iowa Black TM FQ, Iowa Black TM RQ-n1 or IowaBlack TMRQ-n2 (Integrated DNA Technologies, Inc.)

[0058] Examples of non-limiting aspects of this disclosure

[0059] The aspects of the invention described herein (including embodiments) may be advantageous, alone or in combination with one or more other aspects or embodiments. Without limiting the foregoing description, certain non-limiting aspects of this disclosure numbered (1)-(30) are provided below. As will be apparent to those skilled in the art upon reading this disclosure, each of the individually numbered aspects can be used or combined with any of the preceding or following individually numbered aspects. This is intended to support all such combinations of aspects, and is not limited to the combinations of aspects explicitly provided below:

[0060] (1) A DNA aptamer comprising a nucleotide sequence having at least 95% sequence identity with at least one of SEQ ID NO: 2-101.

[0061] (2) The DNA aptamer according to aspect 1, wherein the DNA aptamer consists of about 50 to about 90 nucleotides.

[0062] (3) The DNA aptamer according to aspect 1 or 2, comprising a nucleotide sequence having at least 95% sequence identity with at least one of the following: SEQ ID NO: 29 (M21_28), 45 (M21_44), 60 (M21+RNA_9), 72 (M21+RNA_21), 76 (M21+RNA_25), 78 (M 21+RNA_27), 79(M21+RNA_28), 81(M21+RNA_30), 82(M21+RNA_31), 83(M21+RNA_32) , 90 (M21+RNA_39), 91 (M21+RNA_40), 93 (M21+RNA_42), 94 (M21+RNA_43), 95 (M21+RN A_44), 121 (M21+RNA_9_3Phos), 134 (M21+RNA_11_3Phos), and 135 (M21+RNA_47_3Phos).

[0063] (4) The DNA aptamer according to any one of aspects 1 to 3, comprising a nucleotide sequence having at least 95% sequence identity with at least one of SEQ ID NO: 121 (M21+RNA_9_3Phos), 134 (M21+RNA_11_3Phos) and 135 (M21+RNA_47_3Phos).

[0064] (5) The DNA aptamer according to any one of aspects 1 to 4, wherein the DNA aptamer comprises at least one 1-20 bp truncation.

[0065] (6) The DNA aptamer according to aspect 1 or 2, wherein the DNA aptamer comprises 3'-phosphorylation.

[0066] (7) The DNA aptamer according to any one of aspects 1 to 5, wherein the DNA aptamer has binding affinity for reverse transcriptase.

[0067] (8) The DNA aptamer according to any one of aspects 1 to 7, wherein the DNA aptamer inhibits reverse transcriptase at about 20°C to about 30°C.

[0068] (9) The DNA aptamer according to any one of aspects 1 to 8, wherein the DNA aptamer cannot inhibit reverse transcriptase at about 45°C to about 55°C.

[0069] (10) The DNA aptamer according to any one of aspects 7 to 9, wherein the reverse transcriptase is derived from Moloney mouse leukemia virus (MMLV), avian myeloblastoma virus (AMV) or human immunodeficiency virus type 1 (HIV-1).

[0070] (11) The DNA aptamer according to any one of aspects 7 to 10, wherein the reverse transcriptase comprises a nucleotide sequence having at least 95% sequence identity with SEQ ID NO: 132.

[0071] (12) A composition comprising at least one DNA aptamer according to any one of aspects 1 to 11.

[0072] (13) The composition according to aspect 12, wherein the at least one DNA aptamer is purified by polyacrylamide gel electrophoresis (PAGE).

[0073] (14) The composition according to aspect 12 or 13, wherein the composition further comprises reverse transcriptase.

[0074] (15) The composition according to any one of aspects 12 to 14, wherein the composition further comprises deoxynucleoside triphosphate (dNTP), buffer, or a combination thereof.

[0075] (16) The composition according to any one of aspects 12 to 15, wherein the DNA aptamer is present in the composition at a reverse transcriptase:aptamer ratio of about 1:2 to about 1:8.

[0076] (17) The composition according to any one of aspects 12 to 15, wherein the composition comprises a first DNA aptamer (aptamer 1), a second DNA aptamer (aptamer 2) and optionally a third DNA aptamer (aptamer 3).

[0077] (18) The composition according to aspect 17, wherein the composition comprises reverse transcriptase:aptor 1:aptor 2 in a ratio of about 1:2:2 to about 1:8:8.

[0078] (19) The composition according to aspect 17, wherein the first DNA aptamer comprises a nucleotide sequence having at least 95% sequence identity with SEQ ID NO: 121 (M21+RNA_9_3Phos), the second DNA aptamer comprises a nucleotide sequence having at least 95% sequence identity with SEQ ID NO: 134 (M21+RNA_11_3Phos), and the third DNA aptamer comprises a nucleotide sequence having at least 95% sequence identity with SEQ ID NO: 135 (M21+RNA_47_3Phos).

[0079] (20) The composition according to aspect 17, wherein the first DNA aptamer comprises a nucleotide sequence having at least 95% sequence identity with SEQ ID NO: 121 (M21+RNA_9_3Phos), the second DNA aptamer comprises a nucleotide sequence having at least 95% sequence identity with SEQ ID NO: 134 (M21+RNA_11_3Phos), and the third DNA aptamer comprises a nucleotide sequence having at least 95% sequence identity with SEQ ID NO: 135 (M21+RNA_47_3Phos), and wherein the composition comprises a reverse transcriptase:aptamer 1:aptamer 2:aptamer 3 in a ratio of about 1:2:2:2 to about 1:8:8:8.

[0080] (21) The composition according to aspect 17, wherein the first DNA aptamer comprises a nucleotide sequence having at least 95% sequence identity with SEQ ID NO: 121 (M21+RNA_9_3Phos), the second DNA aptamer comprises a nucleotide sequence having at least 95% sequence identity with SEQ ID NO: 134 (M21+RNA_11_3Phos), and the third DNA aptamer comprises a nucleotide sequence having at least 95% sequence identity with SEQ ID NO: 135 (M21+RNA_47_3Phos), and wherein the composition comprises reverse transcriptase:aptamer 1:aptamer 2:aptamer 3 in a ratio of about 1:6:6:6.

[0081] (22) The composition according to any one of aspects 12 to 20, further comprising an RNA aptamer, wherein optionally the RNA aptamer comprises a sequence having at least 95% sequence identity with SEQ ID NO: 1.

[0082] (23) A kit comprising a DNA aptamer according to any one of aspects 1 to 11, or a composition according to any one of aspects 12 to 22.

[0083] (24) A method for amplifying a target DNA sequence, the method comprising:

[0084] a. Providing a composition according to any one of aspects 12 to 22, the composition further comprising at least one oligonucleotide primer and at least one sample comprising at least one target DNA sequence, wherein the composition is at a temperature of about 20°C to about 30°C, and wherein the reverse transcriptase binds to the at least one DNA aptamer;

[0085] b. Increase the temperature of the composition to release the reverse transcriptase from the at least one DNA aptamer;

[0086] c. Hybridizing the at least one oligonucleotide primer with the at least one sample containing at least one target DNA sequence; and

[0087] d. Initiate DNA polymerase activity and extend the primers with the DNA polymerase to provide additional target DNA sequences.

[0088] (25) The method according to aspect 24, wherein in step (a), the composition is subjected to a temperature of about 20°C to about 30°C for at least 4 hours.

[0089] (26) The method according to aspect 24, wherein in step (a), the composition is subjected to a temperature of about 20°C to about 30°C for at least 12 hours.

[0090] (27) The method according to aspect 24, wherein in step (b), the temperature of the composition is raised to about 45°C to about 55°C.

[0091] (28) A method for identifying at least one DNA aptamer that inhibits at least one reverse transcriptase, the method comprising:

[0092] a. Provide a DNA aptamer library containing DNA aptamers;

[0093] b. In the presence of an RNA aptamer, bring the DNA aptamer close to the at least one reverse transcriptase;

[0094] c. Separating DNA aptamers with high affinity for at least one reverse transcriptase from DNA aptamers with low affinity for at least one reverse transcriptase; and

[0095] d. Amplify the DNA aptamer having a high affinity for the at least one reverse transcriptase to obtain an enriched DNA aptamer library, wherein the at least one DNA aptamer that inhibits the at least one reverse transcriptase can be identified from the enriched DNA aptamer library.

[0096] (29) The method according to aspect 28, wherein the RNA aptamer comprises a sequence having at least 95% sequence identity with SEQ ID NO: 1.

[0097] (30) The method according to aspect 28 or 29, wherein the reverse transcriptase comprises a nucleotide sequence having at least 95% sequence identity with SEQ ID NO: 132.

[0098] The following examples further illustrate the invention, but should not be construed as limiting its scope in any way.

[0099] Example 1

[0100] This example demonstrates the isolation of a DNA aptamer of one aspect of the invention in connection with an MMLV reverse transcriptase mutant.

[0101] In both cases, with and without the previously described reverse transcriptase RNA aptamers, a 40 bp randomized DNA oligonucleotide library with two 21 bp adaptor sequences was used to perform 10 rounds of SELEX with the M21 RT enzyme (total aptamer length 82 bp) (Chen et al., Biochemistry, 33(29): 8746-56 (1994)). After enrichment, the enriched aptamer libraries from each round were sequenced by NGS. Figure 1A and 1B (And Tables 2A and 2B). These results demonstrate that DNA aptamer enrichment occurs significantly earlier in experiments containing RNA aptamers. This finding was unexpected. Without being bound by any particular theory, the earlier DNA aptamer enrichment may be due to a conformational change in reverse transcriptase, which leads to the opening of DNA exit channels in the presence of an RNA template.

[0102] The enriched aptamer sequences obtained from SELEX experiments were ranked by enrichment percentage in both the presence and absence of RNA aptamers (Table 1). For both conditions, the top 50 enriched aptamers were chemically synthesized into 100 nmol DNA oligonucleotides via IDT for subsequent studies. Typically, “one-step” RT-qPCR reactions allow end-users to convert RNA templates to cDNA and perform quantitative PCR using a single master mixture and cycling procedure. In these reactions, the presence of reverse transcriptase can significantly reduce the qPCR signal in later cycles if the reaction is not run immediately after loading. Therefore, a one-step qPCR reaction was used to assess the inhibition of reverse transcriptase by DNA aptamers, in which template was added and the plate was held at room temperature for several hours before running.

[0103] Table 2A

[0104]

[0105] Table 2B

[0106]

[0107] Example 2

[0108] This example demonstrates, using a one-step RT-qPCR, the inhibition of reverse transcriptase by a DNA aptamer of one aspect of the present invention.

[0109] DNA aptamers were tested in the context of one-step RT-qPCR, in which a synthetic RNA genome respiratory virus kit (influenza A, influenza B, SARS-CoV-2, and human RNase P) was amplified, and the signals (Ct and fluorescence intensity) were measured either immediately after template addition on the instrument (time point = 0) or after the plate was kept at 25°C for two hours (time point = 2 hours) before running the instrument.

[0110] In the context of one-step RT-qPCR, all 100 DNA aptamers were tested with and without RNA aptamers. For the binding of RNA aptamers to the M21 RT enzyme, equal volumes of RNA aptamer (2.4 µM, Table 1) and M21 RT enzyme (0.724 µM, Table 1) were mixed and incubated at room temperature for 15 minutes. After incubation, a third volume of DNA aptamer (1.45 µM, Table 1) was added to the RT enzyme bound to the RNA aptamer, and the mixture was incubated again at room temperature for 15 minutes. After incubation, the RT enzyme bound to both RNA and DNA aptamers was placed on ice. For the binding of DNA aptamers to the M21 RT enzyme, equal volumes of DNA aptamer (1.45 µM, Table 1) and M21 RT enzyme (0.724 µM, Table 1) were mixed and incubated at room temperature for 15 minutes. After incubation, the RT enzyme bound to the DNA aptamer was placed on ice. For the standard one-step procedure, an RT enzyme (finally 6.03 nM) bound to both RNA and DNA aptamers is added to a reaction mixture containing: PrimeTime Integrated DNA Technologies, formulated without reverse transcriptase. TM 1-Step 4X wide-range master mixture (1X) and FluVID primer and probe set (Table 1). The assay master mixture was mixed with synthetic RNA ultramer (50 copies / well, Table 1) at a 4:1 ratio to a final volume of 20 µL. Immediately after adding the template at room temperature or two hours later, the assay was performed in qPCR (QuantStudio). TMThe reaction was performed using the following method on 7 Flex aptamers: 15 min at 50 °C, 30 sec at 95 °C, followed by 5 sec at 95 °C and 45 sec at 55 °C, for 45 cycles. The reaction was analyzed and reported by the threshold cycle (Ct, where the threshold was determined by the 0-hour incubation time point) and the endpoint fluorescence (ΔRn) value (Tables 3 and 4). As assessed by endpoint fluorescence and cycle threshold, 15 of the 100 aptamers tested showed significantly improved on-deck reaction mix stability compared to RNA aptamers alone. These 15 aptamers include: M21_28, M21_44, M21+RNA_9, M21+RNA_21, M21+RNA_25, M21+RNA_27, M21+RNA_28, M21+RNA_30, M21+RNA_31, M21+RNA_32, M21+RNA_39, M21+RNA_40, M21+RNA_42, M21+RNA_43, and M21+RNA_44. It is noteworthy that the optimal aptamer remained the same regardless of the addition of the RNA aptamer; however, the optimal aptamer was obtained from SELEX experiments that included the RNA aptamer. Without being bound by any particular theory, these results suggest that RNA is important for isolating the optimal DNA aptamer, but surprisingly, the RNA aptamer provides little or no additional benefit compared to these new DNA aptamers.

[0111] Example 3

[0112] This example demonstrates that the DNA aptamer of one aspect of the present invention inhibits reverse transcriptase at different concentrations.

[0113] This example provides a procedure for evaluating the dosage range of some DNA aptamers from Example 2, and the effect of one-step RT-PCR on reverse transcriptase inhibition. To further “challenge” the candidate DNA aptamers, the qPCR reaction was held at 25°C for 0 or 4 hours after template addition and before instrument running. The DNA aptamers were tested as follows: the DNA aptamers were first bound to M21 RT enzyme at various ratios (1:2, 1:3, 1:5, and 1:10 RT enzyme:aptamer); the aptamer-bound RT enzyme was added to a reaction mixture containing a qPCR master mixture with multiple primers and probes; and the stability of the reaction mixture to be run after template addition was tested.

[0114] For the binding of DNA aptamers to the M21 RT enzyme, equal volumes of different concentrations of DNA aptamers (1.45 µM, 2.17 µM, 3.62 µM, and 7.24 µM, Table 1) and M21 RT enzyme (0.724 µM, Table 1) were mixed and incubated at room temperature for 15 minutes. After incubation, the RT enzyme bound to the DNA aptamer was placed on ice. For the standard one-step procedure, the RT enzyme bound to the DNA aptamer (finally 6.03 nM) was added to a reaction mixture containing the following: PrimeTime Integrated DNA Technologies, Inc., formulated without reverse transcriptase. TM 1-Step 4X wide-range master mixture (1X) and FluVID primer and probe sets (Table 1). The assay master mixture was mixed with synthetic RNA hyperpolymer (50 copies / well, Table 1) at a 4:1 ratio to a final volume of 20 µL. Immediately after adding the template at room temperature or four hours later, the assay was performed in qPCR (QuantStudio). TM The reaction was performed on 7 Flex units using the following method: 45 cycles of incubation at 50°C for 15 minutes, at 95°C for 30 seconds, followed by incubation at 95°C for 5 seconds and at 55°C for 45 seconds. The reaction was analyzed and reported using threshold cycles (Ct, where the threshold was determined by the 0-hour incubation time point) and endpoint fluorescence (ΔRn) values ​​(Table 5). Although all conditions with DNA aptamers showed improved stability of the reaction mixture compared to the control with only RNA, no significant improvement was observed with increasing aptamer concentration, indicating that a 1:2 M21:aptamer ratio is sufficient to achieve maximum effect.

[0115] Example 4

[0116] This example demonstrates the inhibition of reverse transcriptase by a combination of DNA aptamers according to one aspect of the present invention.

[0117] This example provides a procedure for evaluating DNA aptamers that combine an aspect of the present invention, and for seeking an additive effect on reverse transcriptase inhibition via one-step qPCR. The aptamers are challenged after template addition and before instrument operation by holding the reaction at 25°C for 0 or 4 hours. The DNA aptamers are tested as follows: First, two DNA aptamers are bound to M21 RT enzyme; the aptamer-bound RT enzyme is added to a reaction mixture containing a qPCR master mixture with multiple primers and probes; and the stability of the reaction mixture to be run after template addition in the one-step RT-qPCR master mixture is tested.

[0118] For the binding of DNA aptamers to the M21 RT enzyme, equal volumes of two DNA aptamers (1.45 µM, Table 1) and the M21 RT enzyme (0.724 µM, Table 1) were mixed and incubated at room temperature for 15 minutes. After incubation, the RT enzyme bound to the DNA aptamers was placed on ice. For the standard one-step procedure, the RT enzyme bound to the DNA aptamers (finally 6.03 nM) was added to a reaction mixture containing the following: PrimeTime Integrated DNA Technologies, Inc., formulated without reverse transcriptase. TM 1-Step 4X wide-range master mixture (1X) and FluVID primer and probe sets (Table 1). The assay master mixture was mixed with synthetic RNA hyperpolymer (50 copies / well, Table 1) at a 4:1 ratio to a final volume of 20 µL. Immediately after adding the template at room temperature or four hours later, the assay was performed in qPCR (QuantStudio). TM The reaction was performed on 7 Flex using the following method: incubation at 50°C for 15 minutes, at 95°C for 30 seconds, followed by incubation at 95°C for 5 seconds and at 55°C for 45 seconds, for 45 cycles. The reaction was analyzed and reported by threshold cycle (Ct, where the threshold was determined by the 0-hour incubation time point) and endpoint fluorescence (ΔRn) values ​​(Table 5). Among all tested combinations, high endpoint fluorescence and low Ct were the most effective. t With low variance, five combinations were selected as the best combinations. These combinations are: M21_44 + M21+RNA_31, M21+RNA_9 + M21+RNA_27, M21+RNA_9 + M21+RNA_30, M21+RNA_31 + M21+RNA_44, and M21+RNA_43 + M21+RNA_44.

[0119] Example 5

[0120] This example further demonstrates the effectiveness of the DNA aptamer combination of the present invention.

[0121] In this study, DNA aptamers were combined in different ratios, with or without RNA aptamers. These DNA aptamers were challenged after template addition and before instrumental operation by incubating the qPCR reaction at 25°C for 0, 4, and 12 hours. The DNA aptamers were tested as follows: first, RNA aptamers were bound to M21 RT enzyme under appropriate conditions, followed by binding one or two DNA aptamers to M21 RT enzyme; the aptamer-bound RT enzyme was added to a reaction mixture containing a qPCR master mixture with multiple primers and probes; and the stability of the reaction mixture to be run on the instrument was tested after template addition for a one-step RT-qPCR master mixture.

[0122] For conditions containing RNA aptamers, equal volumes of RNA aptamers (2.4 µM, Table 1) and M21 RT enzyme (0.724 µM, Table 1) were mixed and incubated at room temperature for 15 minutes. After incubation, a third volume of DNA aptamers containing one or two DNA aptamers was added to the RT enzyme bound to the RNA aptamers. For M21:DNA aptamer:RNA aptamers in ratios of 1:1:3.3, 1:2:3.3, or 1:5:3.3 (or for M21:DNA aptamer 1:DNA aptamer 2:RNA aptamers in ratios of 1:1:1:3.3, 1:2:2:3.3, or 1:5:5:3.3), the final concentrations were 0.724 µM, 1.45 µM, or 3.62 µM, respectively (Table 1), and the mixture was incubated at room temperature for another 15 minutes.

[0123] For conditions without RNA aptamers, equal volumes of M21 RT enzyme (0.724 µM, Table 1) and a DNA aptamer containing one or two DNA aptamers were added to a third volume of IDTE (pH 7.5), where the final concentrations were 0.724 µM, 1.45 µM, or 3.62 µM for 1:1, 1:2, or 1:5 (or for combinations of 1:1:1, 1:2:2, or 1:5:5), respectively (Table 1), and incubated at room temperature for 15 minutes. After incubation, the RT enzyme bound to the DNA aptamer was placed on ice. For the standard one-step procedure, the RT enzyme bound to the DNA aptamer (finally 6.03 nM) was added to a reaction mixture containing the following: PrimeTime Integrated DNA Technologies, Inc., formulated without reverse transcriptase. TM 1-Step 4X wide-range master mixture (1X) and FluVID primer and probe sets (Table 1). The assay master mixture was mixed with synthetic RNA hyperpolymer (50 copies / well, Table 1) at a 4:1 ratio to a final volume of 20 µL. Immediately after template addition at room temperature, four hours, or twelve hours later, the assay was performed in qPCR (QuantStudio). TM The reaction was performed on 7 Flex using the following method: incubation at 50°C for 15 minutes, at 95°C for 30 seconds, followed by incubation at 95°C for 5 seconds and at 55°C for 45 seconds, for 45 cycles. The reaction was analyzed and reported by threshold cycle (Ct, where the threshold was determined by the 0-hour incubation time point) and endpoint fluorescence (ΔRn) values ​​(Table 7). Among all tested conditions, high endpoint fluorescence and low Ct were the most effective. tWith low variance, M21+RNA_9 + M21+RNA_27 consistently performed as one of the optimal conditions. In fact, M21+RNA_9 + M21+RNA_27 could even successfully amplify RNase P and the SARS-CoV-2 target after 12 hours of incubation at room temperature, although InfA and InfB could not meet the cycle threshold under incubation-free conditions. In almost all cases, the endpoint fluorescence produced by adding the RNA aptamer was lower than that under the corresponding conditions without the RNA aptamer.

[0124] Example 6

[0125] This example demonstrates that the extension blocking 3' modification does not interfere with the inhibition of reverse transcriptase activity by the combined DNA aptamer.

[0126] In this study, 3' DNA modifications were added to the terminal bases of DNA aptamers, preventing DNA polymerase from elongating. The aim of these experiments was to identify 3' modifications that did not interfere with the repression of reverse transcriptase by the combined DNA aptamers. These chemically modified DNA aptamers were synthesized by IDT as 100 nmol DNA oligonucleotides. These DNA aptamers were challenged after template addition and before instrumental operation by incubating the qPCR reaction at 25°C for 4 hours. The DNA aptamers were tested as follows: one or two DNA aptamers were first bound to M21 RT enzyme; the aptamer-bound RT enzyme was added to a reaction mixture containing a qPCR master mixture with multiple primers and probes; and the stability of the reaction mixture to be run on the instrument was tested after template addition for a one-step RT-qPCR master mixture.

[0127] For these experiments, an equal volume of M21 RT enzyme (0.724 µM, Table 1) and a DNA aptamer containing one or two DNA aptamers were added to a third volume of IDTE (pH 7.5), where the final concentrations were 0.724 µM, 1.45 µM, or 3.62 µM for 1:1, 1:2, or 1:5 (or for combinations of 1:1:1, 1:2:2, or 1:5:5), respectively (Table 1), and incubated at room temperature for 15 minutes. After incubation, the RT enzyme bound to the DNA aptamer was placed on ice. For the standard one-step procedure, the RT enzyme bound to the DNA aptamer (finally 6.03 nM) was added to a reaction mixture containing: PrimeTime Integrated DNA Technologies, Inc., formulated without reverse transcriptase. TM 1-Step 4X wide-range master mixture (1X) and FluVID primer and probe sets (Table 1). The assay master mixture was mixed with synthetic RNA hyperpolymer (50 copies / well, Table 1) at a 4:1 ratio to a final volume of 20 µL. Four hours after adding the template at room temperature, the assay was performed in qPCR (QuantStudio).TM The reaction was performed on 7 Flex using the following method: 15 min at 50°C, 30 sec at 95°C, followed by 5 sec at 95°C and 45 sec at 55°C, for 45 cycles. The reaction was analyzed and reported using threshold cycle (Ct) and endpoint fluorescence (ΔRn) values ​​(Table 8). Generally, most 3' modifications that block extension were well tolerated, and the resulting DNA aptamers and combinations of DNA aptamers functioned well to inhibit reverse transcriptase activity in one-step qPCR reactions. DNA aptamers containing 3' phosphate modifications appeared to produce slightly more consistent data than other modified or unmodified aptamers.

[0128] Example 7

[0129] This example demonstrates the binding time range between the reverse transcriptase and the DNA aptamer in one aspect of the present invention.

[0130] This example provides a procedure for determining the optimal binding time between the MMLV RT enzyme and the DNA aptamer to maximize the benefits of stability of the reaction mixture before instrumentation using one-step RT-PCR. The DNA aptamer is tested in the context of one-step RT-qPCR, where a synthetic RNA genome respiratory virus kit (influenza A, influenza B, SARS-CoV-2, and human RNase P) is amplified, and the plate is run on the instrument to measure the signal (Ct and fluorescence intensity) after incubating the plate at 25°C for six hours before instrumentation (time point = 6 hours).

[0131] Single, top-performing DNA aptamers were bound to M21 RT enzyme for 15, 20, and 30 minutes, and the effect on the stability of the reaction mixture was tested in the context of one-step RT-qPCR. For the binding of DNA aptamers to M21 RT enzyme, equal volumes of DNA aptamer (2.9 µM, Table 1) and M21 RT enzyme (0.724 µM, Table 1) were mixed and incubated at room temperature for 15, 20, or 30 minutes. After incubation, the RT enzyme bound to the DNA aptamer was placed on ice. For the standard one-step procedure, the RT enzyme bound to the DNA aptamer (finally 6.03 nM) was added to a reaction mixture containing: PrimeTime Integrated DNA Technologies, Inc., formulated without reverse transcriptase. TM 1-Step 4X wide-range master mixture (1X) and FluVID primer and probe sets (Table 1). The assay master mixture was mixed with synthetic RNA hyperpolymer (50 copies / well, Table 1) at a 4:1 ratio to a final volume of 20 µL. Six hours after template addition at room temperature, the assay was performed in qPCR (QuantStudio). TMThe reaction was carried out using the following method on 7 Flex: 45 cycles were performed with a holding time of 50°C for 15 minutes, 95°C for 30 seconds, followed by a holding time of 95°C for 5 seconds and a holding time of 55°C for 45 seconds. The reaction was analyzed and reported by threshold cycle (Ct) and endpoint fluorescence (ΔRn) values ​​(Table 9). Regarding the stability of the reaction mixture to be used, the 20-minute and 30-minute binding time periods showed significant improvements compared to the 15-minute binding time.

[0132] Example 8

[0133] This example demonstrates the inhibition of reverse transcriptase by the DNA aptamer combination of the present invention using one-step RT-qPCR.

[0134] Compared to single DNA aptamers, paired DNA aptamers have been shown to have a beneficial effect on improving the stability of the reaction mixture before instrumentation. Previous data have demonstrated that M21+RNA_9_3Phos is one of the best DNA aptamers as an independent aptamer. In response, DNA aptamers (100 in total) were paired with M21+RNA_9_3Phos, bound to reverse transcriptase, and tested in the context of one-step RT-qPCR, in which the synthetic RNA genomes of respiratory virus groups (influenza A, influenza B, SARS-CoV-2, and human RNase P) were amplified, and the plates were run on the instrument after being incubated at 25°C for six hours before instrumentation (time point = 6 hours) to measure the signals (Ct and fluorescence intensity).

[0135] For the binding of the DNA aptamer to the M21 RT enzyme, equal volumes of M21+RNA_9_3Phos and unmodified DNA aptamer (1.45 µM each, Table 1) were mixed with the M21 RT enzyme (0.724 µM, Table 1) and incubated at room temperature for 1 hour. After incubation, the RT enzyme bound to the DNA aptamer was placed on ice. For the standard one-step procedure, the RT enzyme bound to the DNA aptamer (finally 6.03 nM) was added to a reaction mixture containing the following: PrimeTime Integrated DNA Technologies, Inc., formulated without reverse transcriptase. TM 1-Step 4X wide-range master mixture (1X) and FluVID primer and probe sets (Table 1). The assay master mixture was mixed with synthetic RNA hyperpolymer (50 copies / well, Table 1) at a 4:1 ratio to a final volume of 20 µL. Six hours after template addition at room temperature, the assay was performed in qPCR (QuantStudio). TMThe reaction was performed on 7 Flex using the following method: 15 min at 50°C, 30 sec at 95°C, followed by 5 sec at 95°C and 45 sec at 55°C, for 45 cycles. The reaction was analyzed and reported using threshold cycle (Ct) and endpoint fluorescence (ΔRn) values ​​(Table 10). Among the 100 aptamers paired with M21+RNA_9_3Phos, two pairs outperformed the others: M21+RNA_9_3Phos with M21+RNA_11, and M21+RNA_9_3Phos with M21+RNA_47. M21+RNA_11 and M21+RNA_47 with 3' phosphorylation modification were ordered for further investigation.

[0136] Example 9

[0137] This example demonstrates the inhibition of reverse transcriptase by the DNA aptamer of one aspect of the present invention at different concentrations.

[0138] This example provides a procedure for evaluating the dosage range of the optimally paired DNA aptamers from Example 8, and the effect of using one-step RT-PCR on reverse transcriptase inhibition. The aptamers are challenged by incubating the reaction at 25°C for 6 hours after template addition and before instrument operation. The DNA aptamers are tested as follows: First, two DNA aptamers are bound to M21 RTase at various ratios (RTase:aptamer 1:aptamer 2 at ratios of 1:2:2, 1:3:3, 1:4:4, 1:6:6, and 1:8:8); the aptamer-bound RTase is added to a reaction mixture containing a qPCR master mixture with multiple primers and probes; and the stability of the reaction mixture to be run after template addition is tested.

[0139] For the binding of DNA aptamers to the M21 RT enzyme, equal volumes of two DNA aptamers (1.45 µM, 2.18 µM, 2.90 µM, 4.34 µM, 5.79 µM, Table 1) and the M21 RT enzyme (0.724 µM, Table 1) were mixed and incubated at room temperature for 25 minutes. After incubation, the RT enzyme bound to the DNA aptamers was placed on ice. For the standard one-step procedure, the RT enzyme bound to the DNA aptamers (finally 6.03 nM) was added to a reaction mixture containing the following: PrimeTime Integrated DNA Technologies, Inc., formulated without reverse transcriptase. TM 1-Step 4X wide-range master mixture (1X) and FluVID primer and probe sets (Table 1). The assay master mixture was mixed with synthetic RNA hyperpolymer (50 copies / well, Table 1) at a 4:1 ratio to a final volume of 20 µL. Six hours after template addition at room temperature, the assay was performed in qPCR (QuantStudio).TM The reaction was performed on 7 Flex using the following method: 15 min at 50 °C, 30 sec at 95 °C, followed by 5 sec at 95 °C and 45 sec at 55 °C, for 45 cycles. The reaction was analyzed and reported using threshold cycle (Ct) and endpoint fluorescence (ΔRn) values ​​(Table 11). An improvement in the stability of the reaction mixture was observed by increasing the ratio of RT-enzyme to aptamer in the two aptamer pairs to a dose of 1:6:6; further addition of aptamer pairs (1:8:8) did not provide any additional benefit. Therefore, a ratio of 1:6:6 was determined to be the optimal concentration of paired aptamers.

[0140] Example 10

[0141] This example demonstrates the inhibition of reverse transcriptase by the DNA aptamer combination of one aspect of the present invention at different concentrations.

[0142] In this study, DNA aptamers were combined and investigated in different ratios to achieve the additional benefit of stability of the reaction mixture before instrumentation. These DNA aptamers were challenged by incubating the qPCR reaction at 25°C for six hours after template addition and before instrumentation. The DNA aptamers were tested as follows: three DNA aptamers were bound to M21 RT-enzyme in various ratios (1:4:4:4, 1:5:5:5, and 1:6:6:6 RT-enzyme:aptamer 1:aptamer 2:aptamer 3); the aptamer-bound RT-enzyme was added to the reaction mixture containing the qPCR master mixture with multiple primers and probes; and the stability of the reaction mixture before instrumentation of the one-step RT-qPCR master mixture generated after template addition was tested.

[0143] For the binding of paired DNA aptamers to the M21 RT enzyme, equal volumes of two DNA aptamers (4.34 µM, Table 1) and the M21 RT enzyme (0.724 µM, Table 1) were mixed and incubated at room temperature for 25 minutes. For the binding of three DNA aptamers to the M21 RT enzyme, equal volumes of three DNA aptamers (2.90 µM, 3.62 µM, and 4.34 µM, Table 1) were mixed with the M21 RT enzyme (0.724 µM, Table 1) and incubated at room temperature for 25 minutes. After incubation, the RT enzyme bound to the DNA aptamers was placed on ice. For the standard one-step procedure, the RT enzyme bound to the DNA aptamers (finally 6.03 nM) was added to a reaction mixture containing the following: PrimeTime Integrated DNA Technologies, Inc., formulated without reverse transcriptase. TM1-Step 4X wide-range master mixture (1X) and FluVID primer and probe sets (Table 1). The assay master mixture was mixed with synthetic RNA hyperpolymer (50 copies / well, Table 1) at a 4:1 ratio to a final volume of 20 µL. Six hours after template addition at room temperature, the assay was performed in qPCR (QuantStudio). TM The reaction was performed using the following method on 7 Flex: 15 min at 50°C, 30 sec at 95°C, followed by 5 sec at 95°C and 45 sec at 55°C, for 45 cycles. The reaction was analyzed and reported using threshold cycle (Ct) and endpoint fluorescence (ΔRn) values ​​(Table 11). Of all the tested conditions, the combination of M21+RNA_9_3Phos + M21+RNA_11_3Phos + M21+RNA_47_3Phos (ratio 1:6:6:6) consistently performed best, outperforming all other conditions (for both two-aptamer and three-aptamer conditions) in terms of high endpoint fluorescence, low Ct, and low variance, and compared to current methods used for IDT PrimeTime. TM RNA aptamers in the 1-Step 4X wide-range master mixture showed significant improvement.

[0144]

[0145]

[0146]

[0147]

[0148]

[0149]

[0150]

[0151]

[0152]

[0153]

[0154]

[0155]

[0156]

[0157]

[0158]

[0159]

[0160]

[0161]

[0162]

[0163]

[0164]

[0165] For Table 2-11, through threshold loop (C t The data includes the endpoint fluorescence (ΔRn) value and the reported data. Samples that do not exceed the amplification threshold are marked as "no amplification" (NA).

[0166]

[0167]

[0168]

[0169]

[0170]

[0171]

[0172]

[0173]

[0174]

[0175]

[0176]

[0177]

[0178]

[0179]

[0180]

[0181]

[0182]

[0183]

[0184]

[0185]

[0186]

[0187]

[0188]

[0189]

[0190]

[0191]

[0192]

[0193]

[0194]

[0195]

[0196]

[0197]

[0198]

[0199]

[0200]

[0201]

[0202]

[0203]

[0204]

[0205]

[0206]

[0207]

[0208]

[0209]

[0210]

[0211]

[0212]

[0213]

[0214]

[0215]

[0216]

[0217]

[0218]

[0219]

[0220]

[0221]

[0222]

[0223]

[0224]

[0225]

[0226]

[0227]

[0228]

[0229]

[0230]

[0231]

[0232]

[0233]

[0234]

[0235]

[0236]

[0237]

[0238]

[0239]

[0240]

[0241]

[0242]

[0243]

[0244]

[0245]

[0246]

[0247]

[0248]

[0249]

[0250]

[0251]

[0252]

[0253]

[0254]

[0255]

[0256]

[0257]

[0258]

[0259]

[0260]

[0261]

[0262]

[0263]

[0264]

[0265] All references cited in this article (including publications, patent applications and patents) are incorporated herein by reference to the same extent that each reference is individually and explicitly indicated to be incorporated and presented in its entirety in this article.

[0266] Unless otherwise stated herein or obviously contradicted by the context, the terms “a,” “the,” and “at least one,” as well as similar indicators, used in the context of describing the invention (particularly in the context of the following claims) should be interpreted to cover both the singular and the plural. The use of the term “at least one” followed by a list of one or more items (e.g., “at least one of A and B”) should be understood to mean one item selected from the listed items (A or B) or any combination of two or more of the listed items (A and B), unless otherwise stated herein or obviously contradicted by the context. Unless otherwise stated, the terms “comprising,” “having,” “including,” and “containing” should be understood as open-ended terms (i.e., meaning “including but not limited to”). Unless otherwise stated herein, the descriptions of numerical ranges herein are intended only as a way of abbreviating each individual value falling within the range, and each individual value is incorporated into this specification as if it were described separately herein. Unless otherwise stated herein or otherwise obviously contradicted by the context, all methods described herein can be performed in any suitable order. Unless otherwise stated, the use of any and all embodiments or exemplary language (e.g., "such") provided herein is intended only to better illustrate the invention and not to limit the scope of the invention. No language in the specification should be construed as indicating that any element not protected by the claims is essential to the practice of the invention.

[0267] This document describes preferred aspects of the invention, including the best modes known to the inventors for carrying out the invention. Variations of those preferred aspects will become apparent to those skilled in the art upon reading the foregoing description. The inventors expect those skilled in the art to appropriately employ these variations, and the inventors intend for the invention to be practiced in ways other than those explicitly described herein. Therefore, the invention includes all modifications and equivalents to the subject matter recited in the appended claims, where permitted by applicable law. Furthermore, the invention covers any combination of the foregoing elements in all possible variations, unless otherwise stated herein or otherwise clearly contradicted by the context.

[0268] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. For example, any nomenclature and techniques described herein in connection with biochemistry, molecular biology, immunology, microbiology, genetics, cell and tissue culture, and protein and nucleic acid chemistry are well known and commonly used in the art. In the event of any conflict, this disclosure (including the definitions) shall prevail. Exemplary methods and materials are described below, but similar or equivalent methods and materials may also be used in the practice or testing of the embodiments and aspects described herein.

[0269] As used herein, the terms “amino acid,” “nucleotide,” “polynucleotide,” “carrier,” “peptide,” and “protein” have their common meanings as understood by a biochemist of ordinary skill in the art. Standard single-letter nucleotides (A, C, G, T, U) and standard single-letter amino acids (A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y) are used herein.

[0270] As used herein, terms such as “include,” “including,” “contain,” “containing,” “having,” etc., mean “comprising.” This disclosure also contemplates other embodiments, whether or not explicitly listed, that “comprising,” “consisting of,” and “substantially constitute” the embodiments or elements presented herein, the embodiments or elements presented herein, and the embodiments or elements presented herein.

[0271] As used herein, the term "or" can be conjunctional or disjunctive.

[0272] As used in this article, the term “substantially” means to a great or significant degree, but not entirely.

[0273] As used herein, the term “about” or “approximately” when applied to one or more values ​​of interest means a value similar to the stated reference value, or within an acceptable range of error for a particular value as determined by one of ordinary skill in the art, the acceptable range of error depending to some extent on how the value was measured or determined, such as limitations of the measurement system. In one aspect, the term “about” means any value, including the integer and decimal parts of the value modified by the term “about”, within a maximum of ±10%. Alternatively, “about” may mean within 3 or more standard deviations according to practice in the art. Alternatively, as for biological systems or processes, the term “about” may mean within an order of magnitude, within 5 times the value in some embodiments, and within 2 times the value in some embodiments. As used herein, the symbol “~” means “about” or “approximately”.

[0274] All ranges disclosed herein include both endpoints as discrete values ​​and all integers and fractions specified within the range. For example, a range of 0.1–2.0 includes 0.1, 0.2, 0.3, 0.4, …, 2.0. If the endpoints are modified by the term “about,” the specified range extends any value within the range by up to ±10%, or within 3 or more standard deviations, including the endpoints.

[0275] As used herein, the term "hybridization" refers to the process of combining two complementary single-stranded nucleic acid molecules and forming a single double-stranded hybrid molecule through base pairing.

[0276] As used in this article, the term “target enrichment” for nucleic acids refers to increasing the relative concentration of a specific nucleic acid species in a sample.

[0277] As used herein, the term "nucleic acid" can refer to DNA, RNA, dsDNA, dsRNA, ssDNA, ssRNA, or a hybrid of DNA / RNA complexes, or a sequence obtained from any source containing both target and non-target sequences. For example, nucleic acid samples can be obtained from artificial sources, through chemical synthesis, or from viruses, prokaryotic or eukaryotic cells including microorganisms. Biological samples can be vertebrates, including or excluding humans, invertebrates, plants, microorganisms, viruses, mycoplasma, fungi, or archaea. Nucleic acid samples can contain whole genome sequences, portions of genome sequences, chromosome sequences, mitochondrial sequences, PCR products, whole genome amplification products, or products of other amplification protocols, such as, but not limited to, cDNA sequences, mRNA sequences, whole transcriptome sequences, exons, or introns. These examples should not be construed as limiting the types of samples applicable to the aspects described herein.

[0278] A polynucleotide having at least, for example, 90-99% “identity” with a reference nucleotide sequence (e.g., SEQ ID NO: 2) means that the nucleotide sequence of the polynucleotide is identical to that of the reference sequence, except that the polynucleotide sequence may include up to about 10 point mutations, additions or deletions per 100 nucleotides of the reference nucleotide sequence without affecting the function or activity of the polynucleotide sequence.

[0279] In other words, to obtain a polynucleotide having at least 90-99% of the same nucleotide sequence as a reference nucleotide sequence, up to 10% of the nucleotides in the reference sequence may be deleted, added, or replaced with another nucleotide, or up to 10% of the total nucleotides in the reference sequence may be inserted into the reference sequence. These mutations in the reference sequence may occur at the 5' or 3' end of the reference nucleotide sequence or at any position between these end positions, and the mutations may be scattered between nucleotides in the reference sequence or scattered in one or more consecutive groups within the reference sequence.

[0280] As mentioned above, two or more polynucleotide sequences can be compared by determining their percentage of identity. The percentage of identity between two sequences is typically described as the number of exact matches between the two aligned sequences divided by the length of the shorter sequence and multiplied by 100. Approximate alignment of nucleic acid sequences is provided by the local homology algorithm of Smith and Waterman, Advances in Applied Mathematics, 2(4): 82-489 (1981).

[0281] The polynucleotides described herein include polynucleotides containing mutations, variations, substitutions, additions, and deletions, as well as specific examples of the polynucleotides described herein. Additionally, polynucleotides can be ribonucleotides (RNA), deoxyribonucleotides (DNA), or combinations thereof, wherein the sequence comprises one or more ribonucleotides or deoxyribonucleotides. The sequence may contain ribonucleotides with, for example, ribothymidine instead of uridine nucleotides to maintain consistency with similar DNA sequences.

[0282] It will be apparent to those skilled in the art that suitable modifications and adaptations can be made to the compositions, formulations, methods, processes, and applications described herein without departing from the scope of any embodiments or aspects thereof. The compositions and methods provided are exemplary and not intended to limit the scope of any specified embodiments. All the various embodiments, aspects, and options disclosed herein can be combined in any variation or iteration. The scope of the compositions, formulations, methods, and processes described herein includes all actual or potential combinations of the embodiments, aspects, options, examples, and preferred embodiments described herein. The exemplary compositions and formulations described herein may omit any component, substitute any component disclosed herein, or include any component disclosed elsewhere herein. The ratio of the mass of any component in any composition or formulation disclosed herein to the mass of any other component in the formulation, or to the total mass of the other components in the formulation, is disclosed herein as if such ratio were explicitly disclosed. If the meaning of any term in any patent or publication incorporated by reference conflicts with the meaning of the term used in this disclosure, the meaning of the term or phrase in this disclosure shall prevail. Furthermore, the foregoing discussion discloses and describes only exemplary embodiments.

Claims

1. A DNA aptamer comprising a nucleotide sequence having at least 95% sequence identity with at least one of SEQ ID NO: 2-101.

2. The DNA aptamer according to claim 1, wherein the DNA aptamer consists of about 50 to about 90 nucleotides.

3. The DNA aptamer according to claim 1 or 2, comprising a nucleotide sequence having at least 95% sequence identity with at least one of the following: SEQ ID NO: 29 (M21_28), 45 (M21_44), 60 (M21+RNA_9), 72 (M21+RNA_21), 76 (M21+RNA_25), 78 (M 21+RNA_27), 79(M21+RNA_28), 81(M21+RNA_30), 82(M21+RNA_31), 83(M21+RNA_32) , 90 (M21+RNA_39), 91 (M21+RNA_40), 93 (M21+RNA_42), 94 (M21+RNA_43), 95 (M21+RN A_44), 121 (M21+RNA_9_3Phos), 134 (M21+RNA_11_3Phos), and 135 (M21+RNA_47_3Phos).

4. The DNA aptamer according to any one of claims 1 to 3, comprising a nucleotide sequence having at least 95% sequence identity with at least one of SEQ ID NO: 121 (M21+RNA_9_3Phos), 134 (M21+RNA_11_3Phos), and 135 (M21+RNA_47_3Phos).

5. The DNA aptamer according to any one of claims 1 to 4, wherein the DNA aptamer comprises at least one 1-20 bp truncation.

6. The DNA aptamer according to claim 1 or 2, wherein the DNA aptamer comprises 3'-phosphorylation.

7. The DNA aptamer according to any one of claims 1 to 5, wherein the DNA aptamer has binding affinity for reverse transcriptase.

8. The DNA aptamer according to any one of claims 1 to 7, wherein the DNA aptamer inhibits reverse transcriptase at about 20°C to about 30°C.

9. The DNA aptamer according to any one of claims 1 to 8, wherein the DNA aptamer cannot inhibit reverse transcriptase at about 45°C to about 55°C.

10. The DNA aptamer according to any one of claims 7 to 9, wherein the reverse transcriptase is derived from Moloney murine leukemia virus (MMLV), avian myeloblastosis virus (AMV), or human immunodeficiency virus type 1 (HIV-1).

11. The DNA aptamer according to any one of claims 7 to 10, wherein the reverse transcriptase comprises a nucleotide sequence having at least 95% sequence identity with SEQ ID NO:

132.

12. A composition comprising at least one DNA aptamer according to any one of claims 1 to 11.

13. The composition according to claim 12, wherein the at least one DNA aptamer is purified by polyacrylamide gel electrophoresis (PAGE).

14. The composition according to claim 12 or 13, wherein the composition further comprises reverse transcriptase.

15. The composition according to any one of claims 12 to 14, wherein the composition further comprises deoxynucleoside triphosphates (dNTPs), buffer solutions, or combinations thereof.

16. The composition according to any one of claims 12 to 15, wherein the DNA aptamer is present in the composition at a reverse transcriptase:aptamer ratio of about 1:2 to about 1:

8.

17. The composition according to any one of claims 12 to 15, wherein the composition comprises a first DNA aptamer (aptamer 1), a second DNA aptamer (aptamer 2), and optionally a third DNA aptamer (aptamer 3).

18. The composition of claim 17, wherein the composition comprises reverse transcriptase:aptor 1:aptor 2 in a ratio of about 1:2:2 to about 1:8:

8.

19. The composition of claim 17, wherein the first DNA aptamer comprises a nucleotide sequence having at least 95% sequence identity with SEQ ID NO: 121 (M21+RNA_9_3Phos), the second DNA aptamer comprises a nucleotide sequence having at least 95% sequence identity with SEQ ID NO: 134 (M21+RNA_11_3Phos), and the third DNA aptamer comprises a nucleotide sequence having at least 95% sequence identity with SEQ ID NO: 135 (M21+RNA_47_3Phos).

20. The composition of claim 17, wherein the first DNA aptamer comprises a nucleotide sequence having at least 95% sequence identity with SEQ ID NO: 121 (M21+RNA_9_3Phos), the second DNA aptamer comprises a nucleotide sequence having at least 95% sequence identity with SEQ ID NO: 134 (M21+RNA_11_3Phos), and the third DNA aptamer comprises a nucleotide sequence having at least 95% sequence identity with SEQ ID NO: 135 (M21+RNA_47_3Phos), and wherein the composition comprises a reverse transcriptase:aptamer 1:aptamer 2:aptamer 3 in a ratio of about 1:2:2:2 to about 1:8:8:

8.

21. The composition of claim 17, wherein the first DNA aptamer comprises a nucleotide sequence having at least 95% sequence identity with SEQ ID NO: 121 (M21+RNA_9_3Phos), the second DNA aptamer comprises a nucleotide sequence having at least 95% sequence identity with SEQ ID NO: 134 (M21+RNA_11_3Phos), and the third DNA aptamer comprises a nucleotide sequence having at least 95% sequence identity with SEQ ID NO: 135 (M21+RNA_47_3Phos), and wherein the composition comprises reverse transcriptase:aptamer 1:aptamer 2:aptamer 3 in a ratio of about 1:6:6:

6.

22. The composition according to any one of claims 12 to 20, further comprising an RNA aptamer, optionally wherein the RNA aptamer comprises a sequence having at least 95% sequence identity with SEQ ID NO:

1.

23. A kit comprising a DNA aptamer according to any one of claims 1 to 11, or a composition according to any one of claims 12 to 22.

24. A method for amplifying a target DNA sequence, the method comprising: a. Providing a composition according to any one of claims 12 to 22, the composition further comprising at least one oligonucleotide primer and at least one sample comprising at least one target DNA sequence, wherein the composition is at a temperature of about 20°C to about 30°C, and wherein the reverse transcriptase binds to the at least one DNA aptamer; b. Increase the temperature of the composition to release the reverse transcriptase from the at least one DNA aptamer; c. Hybridizing the at least one oligonucleotide primer with the at least one sample containing at least one target DNA sequence; and d. Initiate DNA polymerase activity and extend the primers with the DNA polymerase to provide additional target DNA sequences.

25. The method of claim 24, wherein in step (a), the composition is subjected to a temperature of about 20°C to about 30°C for at least 4 hours.

26. The method of claim 24, wherein in step (a), the composition is subjected to a temperature of about 20°C to about 30°C for at least 12 hours.

27. The method of claim 24, wherein in step (b), the temperature of the composition is raised to about 45°C to about 55°C.

28. A method for identifying at least one DNA aptamer that inhibits at least one reverse transcriptase, the method comprising: a. Provide a DNA aptamer library containing DNA aptamers; b. In the presence of an RNA aptamer, bring the DNA aptamer close to the at least one reverse transcriptase; c. Separating DNA aptamers with high affinity for at least one reverse transcriptase from DNA aptamers with low affinity for at least one reverse transcriptase; and d. Amplify the DNA aptamer having a high affinity for the at least one reverse transcriptase to obtain an enriched DNA aptamer library, wherein the at least one DNA aptamer that inhibits the at least one reverse transcriptase can be identified from the enriched DNA aptamer library.

29. The method of claim 28, wherein the RNA aptamer comprises a sequence having at least 95% sequence identity with SEQ ID NO:

1.

30. The method according to claim 28 or 29, wherein the reverse transcriptase comprises a nucleotide sequence having at least 95% sequence identity with SEQ ID NO: 132.